快速访问
文章信息
参考文献
[1]MEI Q, LIU Z, ZUO H, et al. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis [J]. Front Pharmacol, 2021, 12: 797292.
[2]GLASSBERG M K. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape [J]. Am J Manag Care, 2019, 25(11 Suppl): S195–S203.
[3]BARTOLD K, ISKIERKO Z, SHARMA P S, et al. Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers [J]. Biomed J, 2024, 47(4): 100729.
[4]ROQUE W, ROMERO F. Cellular metabolomics of pulmonary fibrosis, from amino acids to lipids [J]. Am J Physiol Cell Physiol, 2021, 320(5): C689–C95.
[5]GAUGG M T, ENGLER A, BREGY L, et al. Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis [J]. Respirology, 2019, 24(5): 437–44.
[6]YAN P, LIU J, LI Z, et al. Glycolysis Reprogramming in Idiopathic Pulmonary Fibrosis: Unveiling the Mystery of Lactate in the Lung [J]. Int J Mol Sci, 2023, 25(1).
[7]HE Y, HAN Y, ZOU L, et al. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis [J]. Sci Rep, 2024, 14(1): 14376.
[8]FAVERIO P, REBORA P, FRANCO G, et al. Alteration of Lipid Metabolism in Patients with IPF and Its Association with Disease Severity and Prognosis: A Case-Control Study [J]. Int J Mol Sci, 2025, 26(12).
[9]OTOUPALOVA E, SMITH S, CHENG G, et al. Oxidative Stress in Pulmonary Fibrosis [J]. Compr Physiol, 2020, 10(2): 509–47.
[10]WALKER V M, DAVEY SMITH G, DAVIES N M, et al. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities [J]. Int J Epidemiol, 2017, 46(6): 2078–89.
[11]SCHMIDT A F, FINAN C, GORDILLO-MARANON M, et al. Genetic drug target validation using Mendelian randomisation [J]. Nat Commun, 2020, 11(1): 3255.
[12]WILLIAMS D M, FINAN C, SCHMIDT A F, et al. Lipid lowering and Alzheimer disease risk: A mendelian randomization study [J]. Ann Neurol, 2020, 87(1): 30–9.
[13]YARMOLINSKY J, BULL C J, VINCENT E E, et al. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer [J]. JAMA, 2020, 323(7): 646–55.
[14]SHIN S Y, FAUMAN E B, PETERSEN A K, et al. An atlas of genetic influences on human blood metabolites [J]. Nat Genet, 2014, 46(6): 543–50.
[15]DUCKWORTH A, GIBBONS M A, ALLEN R J, et al. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study [J]. Lancet Respir Med, 2021, 9(3): 285–94.
[16]吴彤, 杨晶玉, 林盪, 等.基于孟德尔随机化方法探讨脂质和降脂药物与慢性阻塞性肺病的遗传关联 [J].山东大学学报(医学版), 2024, 62(5): 54-63.
[17]ZIEGLER A, PAHLKE F, KONIG I R. Comments on 'Mendelian randomization: using genes as instruments for making causal inferences in epidemiology' by Debbie A. Lawlor, R. M. Harbord, J. A. Sterne, N. Timpson and G. Davey Smith, Statistics in Medicine, DOI: 10.1002/sim.3034 [J]. Stat Med, 2008, 27(15): 2974–6; author reply 6–8.
[18]SKRIVANKOVA V W, RICHMOND R C, WOOLF B A R, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement [J]. JAMA, 2021, 326(16): 1614–21.
[19]王晶, 张国燕, 程杉.孟德尔随机化的良好实践—孟德尔随机化分析的常见设计, 关键挑战及优化 [J].首都医科大学学报, 2023, 44(6): 1087-1094.
[20]YIN K J, HUANG J X, WANG P, et al. No Genetic Causal Association Between Periodontitis and Arthritis: A Bidirectional Two-Sample Mendelian Randomization Analysis [J]. Front Immunol, 2022, 13: 808832.
[21]XIAO G, HE Q, LIU L, et al. Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study [J]. J Transl Med, 2022, 20(1): 475.
[22]BURGESS S, THOMPSON S G. Interpreting findings from Mendelian randomization using the MR-Egger method [J]. Eur J Epidemiol, 2017, 32(5): 377–89.
[23]PANG Z, ZHOU G, EWALD J, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data [J]. Nat Protoc, 2022, 17(8): 1735–61.
[24]ADAPA S R, HUNTER G A, AMIN N E, et al. Correction: Porphyrin overdrive rewires cancer cell metabolism [J]. Life Sci Alliance, 2024, 7(8).
[25]DU X, MA Z, XING Y, et al. Identification and validation of potential biomarkers related to oxidative stress in idiopathic pulmonary fibrosis [J]. Immunobiology, 2024, 229(5): 152791.
[26]YE Q, TALEB S J, WANG H, et al. Molecular Regulation of Heme Oxygenase-1 Expression by E2F Transcription Factor 2 in Lung Fibroblast Cells: Relevance to Idiopathic Pulmonary Fibrosis [J]. Biomolecules, 2022, 12(10).
[27]PAN X, LI J, TU X, et al. Lysine-specific demethylase-1 regulates fibroblast activation in pulmonary fibrosis via TGF-beta1/Smad3 pathway [J]. Pharmacol Res, 2020, 152: 104592.
[28]ARIF M, BASU A, WOLF K M, et al. An Integrative Multiomics Framework for Identification of Therapeutic Targets in Pulmonary Fibrosis [J]. Adv Sci (Weinh), 2023, 10(16): e2207454.
[29]ZHAN J, JARRELL Z R, HU X, et al. A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity [J]. Physiol Rep, 2024, 12(20): e70093.
[30]ROMERO Y, BUENO M, RAMIREZ R, et al. mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts [J]. Aging Cell, 2016, 15(6): 1103–12.
[31]SUMMER R, TODD J L, NEELY M L, et al. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry [J]. Respir Res, 2024, 25(1): 58.
版权与开放获取声明
作为一本开放获取的学术期刊，所有文章均遵循 Creative Commons Attribution 4.0 International License (CC BY 4.0) 协议发布，允许用户在署名原作者的前提下自由共享与再利用内容。所有文章均可免费供读者和机构阅读、下载、引用与传播，EWA Publishing 不会通过期刊的出版发行向读者或机构收取任何费用。